2010   |   2009   |   2008   |   2007   |   2006   |   2005   |   2004   |   2003   |   2002   |   2001   |   2000
 

 
Melville, New York, November 14, 2002
Bovie Medical Corporation (the Company) (OTC Bulletin Board: BOVI), a manufacturer and marketer of electrosurgery products, today announced its financial results for the third quarter and nine months ended September 30, 2002.
 
Revenues for the three months ended September 30, 2002 reached a record $3.0 million when compared to revenues of $2.8 million recorded in the same period a year earlier.
 
For the first nine months of FY 2002, revenues totaled a record $9.3 million, representing an 11% increase over the $8.3 million reported in the comparable period last year.
 
The Company reported a net loss for the third quarter of $64,549 or $(.00) per share versus net income of $312,308 or $.02 per share for the same period a year ago and a net loss of $174,154 or $(.01) per share for the nine months of fiscal 2002, compared to net income of $500,748 or $.03 per share in 2001. The Company attributed the losses to a substantial increase, (up 135%) in research and development for new technologies and products, increased quality control costs coupled with a rise in general and administrative expenses.
 
Subsequent to the close of the third quarter Bovie introduced its Aaron 950, the first high-frequency generator with cutting capabilities. The Aaron 950 offers the physician a wide-range of settings and wattages to perform a variety of surgeries. Introduced at the 100th anniversary of The Health Industry Distributors Association (HIDA) meeting in Chicago, the Aaron 950 was also presented at national meetings for family practice, ophthalmology, and dermatologic surgeons, resulting in sales at each conference.
 
In addition, management is encouraged by the continued progress Bovie is making in the field of electrosurgery and is looking forward to reporting on the anticipated growth in the Company's revenues and bottom line in FY 2003.
 

---

 
Melville, New York - August 14, 2002
Bovie Medical Corporation (the Company) (OTC Bulletin Board: BOVI), a manufacturer and marketer of electrosurgery products, today announced its financial results for the second quarter and six months ended June 30, 2002.
 
Revenues for the three months ended June 30, 2002 increased 14% to a record $3.2 million from $2.81 million a year ago. Revenues for the first half of fiscal 2002, totaled a record $6.2 million, representing an increase of 12% over the $5.5 million recorded in the comparable period last year.
 
Continued investment in research and development (R&D) for new products, including new generator development and J-Plasma technology and increased SG & A expenses, impacted the bottom line; as the Company reported a net loss for the second quarter of $55,149 or $(.00) per share versus net income of $102,601 or $.01 per share for the same period a year ago and a net loss of $109,605 or $(.01) per share for the first six months of FY 2002, compared to a net income of $188,452 or $.01 per share in the same period, a year earlier.
 
Management commented that the Company's investment in R&D leading to the development of a broader product line will have a positive long-term impact on our overall performance. Furthermore, the Company anticipates continued revenue growth over the foreseeable future.
 
Bovie also announced that it received U.S. Food and Drug Administration (FDA) approval to market its Aaron 950 generator, for use in various electrosurgical procedures.
 
Subsequent to close of the first half of FY 2002, Bovie received an initial purchase order of approximately $1.0 million relating to the previously announced contract to manufacture generators, utilized in electrosurgery. This marked the single largest order in Bovie's history.
 

---

 
Melville, New York - June 26, 2002
Bovie Medical Corporation (the Company) (OTC Bulletin Board: BOVI), a manufacturer and marketer of electrosurgery products, today announced that it had entered into an exclusive five-year contract to manufacture generators and accessories utilized in the electrosurgical industry.
 
The contract marks the largest agreement in Bovie's history and management believes that it will have an increasingly significant impact on revenues on a year-to-year basis, during the contract period, which is expected to commence in fiscal 2003. Specific terms of the agreement were not disclosed.
 
Commenting on the new contract Andrew Makrides, president of Bovie Medical Corporation stated, "We are delighted with the confidence demonstrated in Bovie by a premier company in the electrosurgery industry. The contract coupled with the introduction of new products clearly positions Bovie for continued growth."
 

---

 
Melville, New York - May 16, 2002
Bovie Medical Corporation (the Company) (OTC Bulletin Board: BOVI), a manufacturer and marketer of electrosurgery products, today announced its financial results for the first quarter ended March 31, 2002.
 
Revenues for the first three months of fiscal 2002, ended March 31 increased 11 percent to a record first quarter of $3.0 million compared to revenues of $2.7 million in the comparable period last year. Increased R&D, marketing, advertising and new promotion expenses, negatively impacted the Company's bottom line. These were directed at areas that management believes will enhance the Company's long term growth potential through the introduction of new products and greater penetration in the electrosurgery marketplace. Bovie reported a net loss of $54,456 or EPS of $.0 cents per share versus net income of $85,851 or $.01 cent per share for the first quarter of 2001.
 

---

 
Melville, New York - March 15, 2002
Bovie Medical Corporation (the Company) (OTC Bulletin Board: BOVI), a manufacturer and marketer of electrosurgery products, today announced record revenues and net income for fiscal year ended December 31, 2001.
 
Revenues increased to a record $11.5 million representing an 18 percent increase over $9.90 million recorded last year. Net income climbed to $784,293 or $.06 cents per share. In the year prior the Company reported net income of $500,628 or $.04 cents per share.
 
Andrew Makrides, president of Bovie Medical, stated, "Our record performance reflects continuing growth in demand for our expanding product line; particularly in the area of electrosurgery. During the current fiscal year we will be introducing a new Bovie line of electrosurgery generators for the domestic and international markets."
 

---

 
Melville, New York - February 26, 2002
Bovie Medical Corporation (the Company) (OTC Bulletin Board: BOVI), a manufacturer and marketer of electrosurgery products, today announced that the Company finalized a development and manufacturing agreement with SenoRx, Inc., a privately owned company, headquartered in Aliso Viejo, CA.
 
SenoRx, designs, develops and manufactures minimally invasive devices for the diagnosis and treatment of breast cancer. Details of the agreement were not released. However, management anticipates that the agreement will have a very positive impact on revenues.
 
Moshe Citronowicz, chief operating officer of Bovie, stated, "We are excited to be associated with a company at the forefront of breast cancer diagnosis and treatment. This agreement is a clear validation of Bovie's technological ability to develop and manufacture products tailored to meet specific needs and goals."
 
He added that SenoRx's goal is to become a leader in the marketplace by offering products not currently available and procedures that will enhance a breast cancer patient's outcome.
 

---

 
Melville, New York, January 9, 2002
Bovie Medical Corporation (the Company) (OTC Bulletin Board: BOVI), a manufacturer and marketer of electrosurgery products, today announced that it expects to report that the recently completed fourth quarter was the highest revenue quarter in Company history, more than a 15% increase over the fourth quarter of 2000.
 
The Company operates on a calendar fiscal year and anticipates reporting fourth quarter and fiscal 2001 financial results in March.
 
Management attributed the increase to improved demand for its core products coupled with the introduction of new products; particularly in the area of electrosurgical generators.